Mr. Fu oversees the firm’s overall strategy, talent development and is responsible for maintaining the firm’s long-term partnerships with global investors. He has driven successful incubation and buyout strategies, shaping the firm’s differentiated investment approach. Under his leadership, CBC Group was recognised by PEI in 2024 as the #1 private equity firm in Singapore and Asia’s largest healthcare-focused firm, earning this title for the third consecutive year, with the Group’s AUM having grown from US$180 million in 2014 to US$10.5 billion today.
He initiated and led investment transactions including Everest Medicines (HKEX 1952.HK), Hugel Inc. (KOSDAQ:145020), ENSEM Therapeutics (Boston, US) and I-Mab Biopharma (NASDAQ: IMAB), while also being instrumental in incubating several biotech and pharmaceutical companies. He serves as Chairman of the Board for Everest Medicines and I-MAB Biopharma respectively.